The Effectiveness of Repetitive Transcranial Magnetic Stimulation for Weight Loss in Overweight and Obese Patients
1 other identifier
interventional
50
1 country
1
Brief Summary
This doctoral dissertation takes into account epidemiological and clinical data of the international literature about obesity and, generally, increased body weight (BMI≥ 25kg/m2) and their consequences on health. Obesity management challenges many specialties, while, currently, the approved therapeutic methods are dietary intervention, various drugs and, in severe cases, bariatric surgery. All of the above methods show some degree of recurrence, while surgery carries the risk of serious complications. Repetitive transcranial magnetic stimulation (rTMS) is classified into non-invasive brain stimulation methods and utilizes magnetic pulses generated by a coil to bring about changes in the brain. The method has already been approved for the treatment of some disorders, while it seems to help in the fight against many more psychiatric and neurological, mainly, diseases. The aim of the research will be to investigate the effectiveness of TMS in reducing body weight in participants with BMI≥ 25kg/m2. The doctoral dissertation will study the reduction of BMI in obese and overweight patients and the variation of this reduction depending on the severity of obesity and age. In addition, it will investigate the effectiveness by setting as a parameter the observance of a diet. It will also record and statistically process the improvement of symptoms in the spectrum of some psychiatric disorders (eg depressive and psychotic symptoms, psychosomatic disorders). The participants in the research will be hospitalized patients of the Psychiatric Clinic of the University General Hospital of Larissa (PGNL) and citizens. Clearly, patients from other clinics or other citizens can also participate in the research, provided they have a BMI≥ 25kg/m2. They will undergo 20 rTMS sessions (4 per week, for 5 weeks) and an assessment of BMI and some psychiatric symptoms before the start, at the end, 4 weeks after and 6 months after the end of the sessions. The rTMS will be applied to the left dorsal prefrontal cortex (left DLPFC), with an 8-coil in the following conditions: frequency 10 Hz, 75 4-second trains with 26-second intertrain interval, at 120% of the threshold for motor cortex activation. Participants will be divided into three groups: those who will not receive TMS, those who will receive sham TMS and those who will receive active TMS. These patients will then be compared with each other to answer the research questions. The therapeutic protocol presented is based on the international literature, while it presents positive results in the studies in which it has been applied. Prerequisites for participation in the study are patient consent and BMI≥ 25kg/m2. In order to receive TMS, the patient first needs to agree and clarify that he / she does not have an individual or family history of seizures and that he / she does not have a cochlear implant. If the patient wishes, he can withdraw from the study at any stage. In addition to seizures, other side effects of treatment include headache and hearing loss (for which the patient will use earplugs). The present dissertation will contribute to the further understanding of the mechanisms of obesity as well as the development of new therapies for the treatment of the disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jan 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 28, 2022
CompletedFirst Submitted
Initial submission to the registry
April 1, 2025
CompletedFirst Posted
Study publicly available on registry
April 25, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
ExpectedApril 25, 2025
April 1, 2025
3.9 years
April 1, 2025
April 20, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
BMI
From enrollment to the end of the treatment at 5 weeks, follow up of 1 month and 6 months
Food Craving
Scale: Food Cravings Questionnaire-Trait Scores: 15-90 Higher score means worsening of symptoms
From enrollment to the end of the treatment at 5 weeks, follow up of 1 month and 6 months
Secondary Outcomes (3)
Depressive Symptoms
From enrollment to the end of the treatment at 5 weeks, follow up of 1 month and 6 months
Anxiety symptoms
From enrollment to the end of the treatment at 5 weeks, follow up of 1 month and 6 months
Psychosomatic symptoms
From enrollment to the end of the treatment at 5 weeks, follow up of 1 month and 6 months
Study Arms (2)
Active
ACTIVE COMPARATORSham
SHAM COMPARATORInterventions
Eligibility Criteria
You may qualify if:
- Age over 18 years
- BMI \> 25 kg/m²
- Ability to provide written consent
You may not qualify if:
- History of epilepsy
- Active alcohol or substance abuse
- Severe active health condition
- Cochlear implants
- Inability to provide written consent
- BMI \< 25 kg/m²
- Age under 18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universital General Hospital of Larissa
Larissa, Thessaly, 41334, Greece
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
April 1, 2025
First Posted
April 25, 2025
Study Start
January 28, 2022
Primary Completion
January 1, 2026
Study Completion (Estimated)
June 1, 2026
Last Updated
April 25, 2025
Record last verified: 2025-04
Data Sharing
- IPD Sharing
- Will not share